Sleep disorders in Parkinson's disease

International Journal of Clinical Practice

Volumn 57, Issue 9, 2003, Pages 781-787

  Abdelgabar, A ^a   Sharma, J ^b  

^a DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b Department of Elderly Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; LEVODOPA; NORADRENALIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; ZOLPIDEM; ZOPICLONE;

ABDOMINAL PAIN; ANTICHOLINERGIC EFFECT; ANXIETY; BEHAVIOR MODIFICATION; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; DYSTONIA; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MOTOR DYSFUNCTION; NECK PAIN; NERVE DEGENERATION; NEUROCHEMISTRY; PARASOMNIA; PARKINSON DISEASE; PATHOGENESIS; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REBOUND; RESTLESS LEGS SYNDROME; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SLEEP DISORDER; SLEEP TIME; SOMNOLENCE; TREMOR;

ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; PAIN; PARKINSON DISEASE; QUALITY OF LIFE; SLEEP; SLEEP DISORDERS;

EID: 0346328221     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Tandberg E, Larson JP, Nessler EG et al. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995; 5: 541-549.
2. Lees AJ, Blackburn NA, Campbell VL. The nightime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11: 512-519.
3. Jones BE. Basic mechanisms of sleep-wake states. In: Kryger MH, Roth T, Demerit WC, Eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders, 1994: 145-162.
4. Steriade M. Cholinergic blockade of network- and intrinsically generated slow oscillations promotes waking and REM sleep activity patterns in thalamic and cortical neurons. In: Cuello AC, Ed. Progress in brain research, XCV111. Amsterdam: Elsevier Science: 1993; 345-355.
5. Chokroverty S. Sleep, breathing and neurological disorders. In: Chokroverty S, Ed. Sleep disorders medicine: basic science, technical considerations and clinical aspects. Boston: Butterworth-Heinemann, 1994; 295.
6. Nauseida PA. Sleep disorders. In: Koller WC, Ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1987: 371-380.
7. Monk TH, Reynolds CF, Buysse DJ et al. Circadian characteristics of healthy 80-year-olds and their relationship to objectively recorded sleep. J Gerontol 1991; 46: M171-M175.
8. Nausieda PA, Weiner WJ, Kaplan LR et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-194.
9. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998; 13: 895-899.
10. Friedman A. Sleep patterns in Parkinson's disease. Acta Med Pol 1998; 21: 192-199.
11. Bertolucci PH, Andrade LA, Lima JG, Garlin EA. Total sleep deprivation and Parkinson's disease. Arq Neuropsiquitar 1987; 45: 224-230.
12. Askenasy JJM, Yahr MD. Reversal of sleep disruption in Parkinson's disease by anti-Parkinson therapy: a preliminary study. Neurology 1985; 35: 527-532.
13. Askenasy JJM, Yahr MD. Different laws govern motor activity in sleep than in wakefulness. J Neurol Trans 1990; 79: 103-111.
14. Askenasy JJM, Yahr MD. Parkinsonian tremor loses its alternating aspect during non-REM and is inhibited by REM sleep. J Neurol Neurosurg Psychiatry 1990; 53: 749-753.
15. Trenkwalder C, Walters AS, Hening WA et al. Positron emission tomography studies in restless legs syndrome. Mov Disord 1999; 14: 141-145.
16. Routtinen HM, Partinen M, Hublin C et al. An FDOPA PET study in patients with periodic leg movement disorder and restless legs syndrome. Neurology 2000; 54: 502-504.
17. Askenasy JJM, Weitzman ED, Yahr MD. Are periodic movements in a sleep a basal ganglia dysfunction? J Neural Transm 1985; 70: 337-348.
18. Parkinson J. Essay on the shaking palsy. London: Sherwood Nealy & Jones, 1817.
19. Brain WR. Clinical neurology. London: Oxford University Press, 1914; 67.
20. Laihinen A, Alihanka J, Raitasuo S, Rinne UK. Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease. Acta Neurol Scand 1987; 76: 64-68.
21. Goetz CG, Tanner CM, Levy M et al. Pain in Parkinson's disease. Mov Disord 1986; 1: 45-49.
22. Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology (Cleveland) 1976; 26: 423-429.
23. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995; 60(1): 3-38.
24. Sandyk R. Pineal melatonin and sensory symptoms in Parkinson's disease. Neurol Sci 1989; 10(4): 399-403.
25. Ford B, Louis ED, Greene P et al. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 1996; 11(4): 421-426
26. Hillen ME, Sage JI, Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996; 47: 1180-1183.
27. Martinez-Martin P, Grandas F, Linazasoeo G et al. Conversion to controlled-release levodopa/carbidopa treatment and quality of life and quality of life as measured by the Nottingham Health Profile. The STAR Study Group. Neurologia 1999; 14: 338-343.
28. Bleasdale-Barr KM, Mathias CJ. Neck and other muscles pain in autonomic failure: their association with orthostatic hypotension. J R Soc Med 1998; 91: 355-359.
29. Quigley EM. Gastrointestinal dysfunction in Parkinson's disease. Semin Neurol 1996; 3: 245-250.
30. Kains JP, Hardy JC, Chevalier C et al. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine. Acta Clin Belg 1990; 45: 306-310.
31. Goetz CG, Wilson RS, Tanner CM, Garron DG. Relationships among pain, depression and sleep alterations in Parkinson's disease. Adv Neurol 1987; 45: 345-347.
32. Chokroverty S. The spectrum of ventilatory disturbances in movement disorders. In: Chokroverty S, Ed. Movement disorders. Cosra Mesa: PMA, 1990; 365.
33. Hardie RJ, Efthimiou J, Stern GM. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry 1986; 50: 1326.
34. Hovestadt A, Bogaard JM, Meerwaldt JD et al. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989; 52: 329-333.
35. Lilker ES, Woolf CR. Pulmonary function in Parkinson's syndrome. Can Med Assoc J 1968; 99: 752-757.
36. Obenour WH, Stevens PM, Cohen AA et al. The causes of abnormal pulmonary function in Parkinson's disease. Am Rev Respir Dis 1972; 105: 382-387.
37. Vas CJ, Parsonage M, Lord OC. Parkinsonism associated with laryngeal spasm. J Neurol Neurosurg Psychiatry 1965; 28: 401-403.
38. Vincken WG, Gauthier SG, Dollfuss RE et al. Involvement of upper airway muscles in extrapyramidal disorders. N Engl J Med 1984; 311: 439-442.
39. Weiner WJ, Goetz G, Nausidea PA et al. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978; 88: 327-331.
40. Efthimiou J, Ellis SJ, Hardie RJ et al. Sleep apnoea in idiopathic and postencephalitic parkinsonism. In: Yahr MD, Bergmann KJ, Eds. Parkinson's disease. New York: Raven Press, 1986; 275.
41. Purdy A, Hahn A, Barnett JM et al. Familial fatal parkinsonism with alveolar hypoventilation and mental depression. Ann Neurol 1979; 6: 523-531.
42. Starkstein SE, Robinson RG. Mood disorders in neurodegenerative disease. Semin Clin Neuropsychiatry 1996; 1: 272-281.
43. Copeland JRM, Davidson JA, Dewey ME. The prevalence and outcome of anxious depression in elderly people aged 65 and over living in the community. In: Racagni G, Smeraldi E, Eds. Anxious depression. New York: Raven Press, 1992: 43-47.
44. Mayeux R, Stern Y, Williams JBW et al. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986; 143: 756-759.
45. Gold PW, Goodwin FK, Chrousus GP. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med 1988; 319: 348-353.
46. Heninger GR, Charney DS. Monamine receptor systems and anxiety disorders. Psychiatr Clin North Am 1988; 11: 309-326.
47. Nutt D, Laurence C. Panic attacks: a neurochemical overview of models and mechanism. Br J Psychiatry 1992; 160: 165-178.
48. Roy-Byrne PD, Uhde TW, Sack DA et al. Plasma HVA and anxiety in patients with panic disorder. Biol Psychiatry 1986; 21: 949-953.
49. Menza MA, Rosen RC. Sleep in Parkinson's disease: the role of depression and anxiety. Psychosomatics 1995; 36: 262-266
50. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug induced psychiatric states. Adv Neurol 1995; 65: 115-138.
51. Arnulf I, Bonnet A-M, Damier P et al. Hallucinations, REM sleep, and Parkinson's disease. Neurology 2000; 55: 281-288.
52. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuro-psychological test. Age Ageing 1999; 28: 39-43.
53. Mahieux F, Fenelon G, Flahault A et al. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-183.
54. De Vos RAI, Jansen ENH, Yilmazer D et al. Pathological and clinical features of Parkinson's disease with and without dementia. In: Perry R, McKeith I, Perry E, Eds. Dementia with Lewy bodies. Cambridge: Cambridge University Press, 1996: 255-267.
55. Bliwise DL: Dementia. In: Kryger MH, Roth T, Dement WC, Eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders, 1994; 790.
56. Loewensten RJ, Weingartner H, Gillin JC et al. Disturbances of sleep and cognitive functioning in patients with dementia. Neurobiol Aging 1982; 3: 371-377.
57. Montplaisir J, Peti D, Lorrain D et al. Sleep in Alzheimer's disease: further considerations on the role of brain stem and forebrain cholinergic populations in sleep- wake mechanisms. Sleep 1995; 18: 145-148.
58. Johns MW. Reliability and factor analysis of the Epworth sleepiness scale. Sleep 1992; 15: 376-381.
59. Jansen ENH, Meerwaldt JD. Madopar HBS in parkinsonian patients with nocturnal akinasia. Clin Neurol Neurosurg 1988; 90: 35-39.
60. Lees AJ. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early morning disabilities in Parkinson's disease. Eur Neurol 1987; 27(suppl 1): 126-134.
61. Benes H, Kurella B, Kummer J et al. Rapid onset of action of levodopa in restless legs syndrome: a double blind, randomised, multicentre, crossover trial. Sleep 1999; 22: 1073-1081.
62. Chesson AL, Wise M, Davila D et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999; 22: 961-968.
63. Montplaisir J, Nicolas A, Denesic R et al. Restless legs syndrome improved by pramipexole: a double blind randomised trial. Neurology 1999; 52: 938-943.
64. 2-agonist cabergoline: an open clinical trial. Sleep 2000; 23: 349-354.
65. Corrigan M, Denahan AQ, Wright CE et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65.
66. Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 2001; 56(suppl 5): S52-S53.
67. Lader M. Anxiety or depression during withdrawal of hypnotic treatments. J Psychosom Res 1994; 38(suppl 1): 113-123.
68. Katsunuma H, Shimizu T, Ogawa K et al. Treatment of insomnia by concomitant therapy with zopiclone and aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 1998; 52: 198-200.
69. Lader M. Zopiclone: is there any dependence and abuse potential? J Neurol 1997; 244(4 suppl 1): S18-S22.
70. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331-339.
71. Schenck CH, Mahowald MW. Polysomnographic, neurologic, psychotic, and clinical outcome report on 70 consecutive cases with the REM sleep behaviour disorder (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Clev Clin J Med 1990; 57: 19-24.
72. Moskovitz C, Moses K, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135: 669-675.
73. Aersland D, Larsen JP, Tandberg E et al. Predictors of nursing home placements in Parkinson's disease: a population-based prospective study. J Am Geriatr Soc 2000; 48: 938-942.
74. McKeith IG, Grace J B, Walker Z et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Geriatr Psychiatry 2000; 15: 387-392.
75. Wilson SAK. Paralysis agitans. In: Bruce AN, Ed. Neurology. New York: Hafner Publishing Co 1970; 787-804.
76. Birkmayer W, Daniel CZ, Neumayer E, Riederer P. Nucleus ruber and L-dopa psychosis: biochemical and post-mortem findings. J Neural Trans 1974; 35: 93-116.
77. Birkmayer W, Reiderer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Trans 1975; 35: 175-182.
78. Frucht S, Rogers MD, Greene PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-1910.
79. Chamraj SC, Schulzer M, Stoessl J et al. Daytime sleepiness and Parkinson treatment. Neurology 2001; 56(suppl 3): A213. Abstract.
80. Lang AE, Hobson DE, Martin W, Rivest J. Excessive daytime sleepiness and sudden onset sleep in Parkinson's disease: a survey from 18 Canadian movement disorders clinics. Neurology 2001; 56(suppl 3): A307. Abstract.
81. Carbonari E, De Notaris R, De Gasperi D et al. Daily somnolence and night sleep in Parkinson's disease: role of treatment and disease severity. Neurology 2001; 569(suppl 3): A 213-A214. Abstract.
82. Jones BE. Basic mechanisms of sleep-wake states. In: Kryger MH, Roth T, Dement WC, Eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders, 2000; 140-142.
83. Stover NP, Okum MS, Wan SRL. Sleep 'attacks' and excessive daytime sleepiness in Parkinson's disease: a survey of 200 consecutive patients. Neurology 2001; 56(suppl 3): A213. Abstract.
84. Ferreira JJ, Galitzky M, Thalamas C et al. Ropinirole induced sedation: a randomised placebo-controlled study in healthy in healthy volunteers. Neurology 2001; 56(suppl 3): A214. Abstract.
85. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990; 5: 280-285.
86. Van Hilten JJ, Weggeman M, Vander Velde EA et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neurol Trans 1993; 5: 235-244.
87. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14: 922-927.
88. Ferreira JJ, Pona N, Costa J et al. Somnolence as an adverse drug reaction of antiparkinsonian drugs: a meta-analysis of published randomised placebo controlled trials. Mov Disord 2000; 15(supp 3): 128.
89. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord 2000; 15: 212-215.